Stifel Nicolaus began coverage on shares of Avalo Therapeutics (NASDAQ:AVTX - Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $36.00 price objective on the stock.
Several other equities research analysts have also recently commented on AVTX. Piper Sandler initiated coverage on shares of Avalo Therapeutics in a research report on Friday, February 28th. They issued an "overweight" rating and a $48.00 target price for the company. HC Wainwright restated a "neutral" rating on shares of Avalo Therapeutics in a report on Thursday, March 20th. Wedbush restated an "outperform" rating and issued a $18.00 price objective on shares of Avalo Therapeutics in a report on Thursday, March 20th. Finally, BTIG Research initiated coverage on shares of Avalo Therapeutics in a research note on Thursday, December 19th. They set a "buy" rating and a $40.00 target price for the company. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Avalo Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $33.00.
View Our Latest Report on AVTX
Avalo Therapeutics Trading Down 3.1 %
Shares of AVTX traded down $0.27 during mid-day trading on Tuesday, reaching $8.46. The company's stock had a trading volume of 36,738 shares, compared to its average volume of 72,453. Avalo Therapeutics has a 52 week low of $5.99 and a 52 week high of $22.47. The company's fifty day moving average price is $7.62 and its two-hundred day moving average price is $9.14.
Hedge Funds Weigh In On Avalo Therapeutics
A number of hedge funds have recently added to or reduced their stakes in AVTX. Velan Capital Investment Management LP purchased a new position in shares of Avalo Therapeutics in the fourth quarter worth $817,000. BVF Inc. IL raised its position in Avalo Therapeutics by 7.2% in the 4th quarter. BVF Inc. IL now owns 1,036,679 shares of the company's stock worth $7,703,000 after buying an additional 69,679 shares during the last quarter. Allostery Investments LP bought a new position in Avalo Therapeutics during the 4th quarter valued at about $545,000. Northern Trust Corp purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $168,000. Finally, Tower Research Capital LLC TRC lifted its position in Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after purchasing an additional 3,754 shares during the period. 87.06% of the stock is currently owned by hedge funds and other institutional investors.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Featured Articles
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
